A New And Improved Diabetes Drug
The phase 3 SURPASS trials, which were published in 2021, proved that tirzepatide reduces blood sugar and promotes weight reduction better than other type 2 diabetes (T2D) drugs. Now, a new study evaluating the time required to achieve blood glucose goals shows that tirzepatide meets blood sugar control and weight reduction goals quicker than existing diabetes drugs. The latest analyses of the SURPASS-2 and SURPASS-3 trials, which were presented at 2022’s European Association for the Study of Diabetes (EASD) Annual Meeting in Stockholm, Sweden, discovered that adults treated with various doses of injectable tirzepatide (5, 10, and 15 mg) reached blood glucose targets about four weeks sooner than those treated with injectable semaglutide (1 mg), and between four and 12 weeks sooner than those treated with once-daily insulin (degludec; iDeg), along with diet and exercise and oral glucose-lowering medications....